Vanda Pharmaceuticals (VNDA) Tops Q2 EPS by 5c, provides guidance

Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of ($0.08), $0.05 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $50.5 million versus the consensus estimate of $52.4 million.

GUIDANCE:

Vanda Pharmaceuticals sees FY2024 revenue of $180-210 million, versus the consensus of $220.2 million.

Year-end 2024 Cash: $360 to $390 million

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.

You May Also Be Interested In

• SYNNEX Corp. (SNX) Tops Q3 EPS by $1.04, Beats on Revenue; Offers Q4 Guidance
• Arcturus Therapeutics (ARCT) Reiterated at Overweight by Cantor Fitzgerald
• Jefferies Reiterates Buy Rating on McDonald's (MCD)